

Thierry Lefevre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9224314/publications.pdf>

Version: 2024-02-01

89
papers

6,821
citations

94433

37
h-index

62596

80
g-index

98
all docs

98
docs citations

98
times ranked

6420
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of length of stay after transfemoral transcatheter aortic valve replacement: results from the FRANCE TAVI registry. <i>Clinical Research in Cardiology</i> , 2021, 110, 40-49.	3.3	18
2	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	1.7	7
3	Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2020, 141, 243-259.	1.6	118
4	Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE III and BIOFLOW II trials. <i>International Journal of Cardiology</i> , 2020, 300, 60-65.	1.7	13
5	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2020, 125, 441-448.	1.6	9
6	Safety and effectiveness of a transaortic approach for TAVI: procedural and midterm outcomes of 265 consecutive patients in a single centre. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 400-407.	1.1	5
7	Role for Vascular Factors in Long-Term Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 125, 1884-1889.	1.6	1
8	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1067-1079.	1.7	57
9	Evaluation of length of stay after transfemoral transcatheter aortic valve implantation with SAPIEN 3 prosthesis: A French multicentre prospective observational trial. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 391-400.	1.6	7
10	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 198-207.	1.7	13
11	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO3 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E688-E694.	1.7	1
12	Chimney Stenting for Coronary Occlusion During TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 751-761.	2.9	90
13	Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1058-1068.	2.9	36
14	Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study. <i>EuroIntervention</i> , 2020, 16, 654-662.	3.2	2
15	General Anesthesia or Conscious Sedation for Transfemoral Aortic Valve Replacement with the SAPIEN 3 Transcatheter Heart Valve. <i>International Heart Journal</i> , 2020, 61, 713-719.	1.0	4
16	Implementation of the transradial approach as an alternative vascular access for transcatheter aortic valve replacement guidance: Experience from a high-volume center. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1367-1373.	1.7	18
17	Development of a Risk Score Based on Aortic Calcification to Predict 1-Year Mortality After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 123-132.	5.3	32
18	Significance of the CAPRI risk score to predict heart failure hospitalization post-TAVI: The CAPRI-HF study. <i>International Journal of Cardiology</i> , 2019, 296, 98-102.	1.7	9

#	ARTICLE	IF	CITATIONS
19	Carotid versus femoral access for transcatheter aortic valve implantation: a propensity score inverse probability weighting study. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 1140-1146.	1.4	21
20	Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: Insights from 1544 patients included in the SOURCE 3 registry. <i>International Journal of Cardiology</i> , 2019, 296, 32-37.	1.7	9
21	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 420-433.	1.6	263
22	TCT-276 Individual Patient Data Analysis of the BIOFLOW Study Program Comparing Safety and Efficacy of a Bioresorbable Polymer Sirolimus-Eluting Stent to a Durable Polymer Everolimus-Eluting Stent. <i>Journal of the American College of Cardiology</i> , 2019, 74, B275.	2.8	0
23	Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. <i>European Journal of Heart Failure</i> , 2019, 21, 1619-1627.	7.1	149
24	Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008434.	3.9	234
25	Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2449-2459.	2.9	46
26	Derivation and Validation of a Chronic Total Coronary Occlusion Intervention Procedural Success Score From the 20,000-Patient EuroCTO Registry. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 335-342.	2.9	99
27	Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 113-123.	1.6	4
28	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	1.7	35
29	Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007597.	3.9	46
30	Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2019, 124, 90-97.	1.6	11
31	Habitual Physical Activity in Older Adults Undergoing TAVR. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 781-789.	2.9	29
32	Sex-Specific Determinants of Outcomes After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005363.	2.2	36
33	Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011111.	3.7	17
34	Is sex associated with adverse outcomes after percutaneous coronary intervention for CTO?. <i>International Journal of Cardiology</i> , 2019, 288, 29-33.	1.7	10
35	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	1.6	19
36	Vibrational Circular Dichroism Reveals Supramolecular Chirality Inversion of β -Synuclein Peptide Assemblies upon Interactions with Anionic Membranes. <i>ACS Nano</i> , 2019, 13, 3232-3242.	14.6	30

#	ARTICLE	IF	CITATIONS
37	Femoral Versus Nonfemoral Peripheral Access for Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2728-2739.	2.8	75
38	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. <i>Canadian Journal of Cardiology</i> , 2019, 35, 199-207.	1.7	7
39	Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use. <i>Journal of the American College of Cardiology</i> , 2019, 73, 13-21.	2.8	85
40	One-Year Outcomes of a European Transcatheter Aortic Valve Implantation Cohort According to Surgical Risk. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e006724.	3.9	11
41	Bicuspid Aortic Valve Anatomy and Relationship With Devices: The BAVARD Multicenter Registry. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007107.	3.9	125
42	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	1.7	22
43	Joint consensus on the use of OCT in coronary bifurcation lesions by the European and Japanese bifurcation clubs. <i>EuroIntervention</i> , 2019, 14, e1568-e1577.	3.2	51
44	Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2019, 15, 90-98.	3.2	99
45	EuroCTO Club 2018 meeting: "Experts Live" in Toulouse. <i>EuroIntervention</i> , 2019, 14, e1814-e1817.	3.2	1
46	The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS) Tj ETQq0 0 0 rBT /Overlock 10 Tf	1.7	46
47	«Todo debe hacerse tan simple como sea posible, pero no más simple». <i>Revista Espanola De Cardiologia</i> , 2018, 71, 418-419.	1.2	1
48	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1-12.	2.9	77
49	Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). <i>European Heart Journal</i> , 2018, 39, 676-684.	2.2	91
50	Right Ventricular Pseudoaneurysm After Percutaneous Tricuspid Valve-in-valve Implantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 1070.	0.6	0
51	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. <i>American Heart Journal</i> , 2018, 200, 44-50.	2.7	111
52	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 338-343.	1.3	25
53	«Everything Should be Made as Simple as Possible but Not Simpler». <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 418-419.	0.6	1
54	Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. <i>Circulation</i> , 2018, 138, 2597-2607.	1.6	109

#	ARTICLE	IF	CITATIONS
55	TCT-14 Final 5-Year Outcomes of the REPRISE II Study: Long-term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve. <i>Journal of the American College of Cardiology</i> , 2018, 72, B6.	2.8	2
56	Temporal Trends in Chronic Total Occlusion Interventions in Europe. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006229.	3.9	105
57	Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2195-2203.	2.9	27
58	Interaction Between Frailty and Access Site in Older Adults Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2185-2192.	2.9	16
59	Coronary Artery Fenestration. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1905-1907.	2.9	9
60	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	1.6	18
61	Impact of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty on Procedural and Clinical Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1956-1965.	2.9	42
62	Double Anomalous Aortic Origin of a Coronary Artery With Intramural Course. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, e153-e155.	2.9	1
63	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With Durable Polymer Everolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 995-1002.	2.9	63
64	Malnutrition and Mortality in Frail and Non-Frail Older Adults Undergoing Aortic Valve Replacement. <i>Circulation</i> , 2018, 138, 2202-2211.	1.6	79
65	Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. <i>American Journal of Cardiology</i> , 2018, 122, 1028-1035.	1.6	47
66	Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. <i>New England Journal of Medicine</i> , 2018, 379, 2297-2306.	27.0	1,276
67	TAVI: Simplification Is the Ultimate Sophistication. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 96.	2.4	16
68	Seudoaneurisma ventricular derecho tras implante valve-in-valve tricuspídeo. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 1070.	1.2	2
69	Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 13, e1794-e1803.	3.2	28
70	Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 13, 1540-1553.	3.2	185
71	Characteristics of stent thrombosis in bifurcation lesions analysed by optical coherence tomography. <i>EuroIntervention</i> , 2018, 13, 2174-2181.	3.2	5
72	Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 14, e467-e474.	3.2	60

#	ARTICLE	IF	CITATIONS
73	Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 14, 112-120.	3.2	94
74	Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1027-1037.	1.7	8
75	Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1048-1056.	2.9	117
76	Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1016-1026.	1.7	4
77	Incidence and predictors of coronary obstruction following transcatheter aortic valve implantation in the real world. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 1192-1197.	1.7	28
78	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2017, 120, 2025-2030.	1.6	18
79	Frailty in Older Adults Undergoing Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 70, 689-700.	2.8	561
80	Impact of coronary artery disease in patients undergoing transcatheter aortic valve replacement: Insights from the FRANCE2 registry. <i>Clinical Cardiology</i> , 2017, 40, 1316-1322.	1.8	18
81	Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1637-1647.	2.8	109
82	Acute and 30-Day Outcomes in Women After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1589-1600.	2.9	85
83	Transcatheter Replacement of Failed Bioprosthetic Valves. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	104
84	Prognostic value of aortic root calcification volume on clinical outcomes after transcatheter balloon-expandable aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1105-1113.	1.7	19
85	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2860-2868.	2.8	116
86	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 162.	7.4	762
87	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 483-493.	2.1	24
88	Sex-Related Differences in Clinical Presentation and Outcome of Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2012, 59, 566-571.	2.8	179
89	Impact of Post-Procedural Aortic Regurgitation on Mortality After Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1247-1256.	2.9	150